Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil R Smith

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Molecular Cancer Therapeutics|June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivoDavid W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Cancer Discovery|May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAlex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
International Journal of Oncology|May 4, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerSandra R Brave, Rajesh Odedra, Neil H James, et al.
Molecular Cancer Therapeutics|June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivoDavid W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Cancer Discovery|May 15, 2016
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialAlex Pearson, Elizabeth Smyth, Irina S Babina, et al.
Cancer Research|May 19, 2005
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerStephen R Wedge, Jane Kendrew, Laurent F Hennequin, et al.
Pageof 4